<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11688">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024906</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000073</org_study_id>
    <secondary_id>UL1TR000001</secondary_id>
    <secondary_id>HD002528</secondary_id>
    <nct_id>NCT02024906</nct_id>
  </id_info>
  <brief_title>Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants</brief_title>
  <official_title>Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jill Hamilton-Reeves, PhD RD LD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Soy Nutrition Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help the researchers understand if using a soy supplement
      impacts cardiovascular disease risk factors in patients with subclinical hypothyroidism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot trial is a double blind, randomized, parallel arm trial. Eighty participants with
      subclinical hypothyroidism will be randomized to consume either soy protein isolate  or milk
      protein isolate for 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in the cardiometabolic profile</measure>
    <time_frame>Change from Baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the role of isoflavone intake on cardiovascular disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in thyroid function</measure>
    <time_frame>Change from Basesline to 8 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be monitored through measuring thyroid stimulating hormone (TSH) and free thyroxine (T4) in participants while on the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in thyroid function</measure>
    <time_frame>Change from Basesline to 4 Weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be monitored through measuring thyroid stimulating hormone (TSH) and free thyroxine (T4) in participants while on the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the cardiometabolic profile</measure>
    <time_frame>Change from Basesline to 4 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the role of isoflavone intake on cardiovascular disease.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Subclinical Hypothyroid</condition>
  <arm_group>
    <arm_group_label>soy protein isolate (SPI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 grams soy protein isolate (SPI) containing approximately 30 mg/d isoflavones</description>
  </arm_group>
  <arm_group>
    <arm_group_label>milk protein isolate (MPI)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>milk protein isolate (MPI) containing 0 mg/d isoflavones</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy protein isolate (SPI)</intervention_name>
    <arm_group_label>soy protein isolate (SPI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>milk protein isolate (MPI)</intervention_name>
    <arm_group_label>milk protein isolate (MPI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with subclinical hypothyroidism (otherwise healthy volunteers)

          -  Adults aged 25 - 70 yrs.

          -  Willing to avoid consumption of soy/other isoflavone containing foods (i.e. some
             snack bars) during the study.

          -  Willing to avoid consumption of dietary (other than multivitamin) and herbal
             supplements during the study.

        Exclusion Criteria:

          -  Taking drugs that interfere with thyroid function

          -  Planning pregnancy in the next 6 months

          -  Taking drugs that lower lipids, blood pressure, or sensitize insulin

          -  Regular consumption of soy products (&gt;20 g/wk)

          -  Consumption of soyfoods within 90 days prior to enrollment.

          -  Known history of soy or milk allergy or intolerance.

          -  Taking antibiotics during the intervention

          -  Active viral infections such as Human immunodeficiency virus (HIV) positive or
             hepatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Hamilton-Reeves, PhD, RD, LD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jill Hamilton-Reeves, PhD, RD, LD</last_name>
      <phone>913-588-7650</phone>
      <email>jhamilton-reeves@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>December 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center Research Institute</investigator_affiliation>
    <investigator_full_name>Jill Hamilton-Reeves, PhD RD LD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>isoflavone</keyword>
  <keyword>CVD</keyword>
  <keyword>soy intake</keyword>
  <keyword>subclinical hypothyroid</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
